References
- Szabo TL. Diagnostic ultrasound imaging: inside out. 2nd edition. Academic Press; Elsevier Inc. 2014. doi: 10.1016/C2011-0-07261-7
- Sennoga CA, Kanbar E, Auboire L, Dujardin PA, Fouan D, Escoffre JM, et al. Microbubble-mediated ultrasound drug-delivery and therapeutic monitoring. Expert Opin Drug Deliv 2017; 14: 1031–43. doi: 10.1080/17425247.2017.1266328
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71: 209–49. doi: 10.3322/caac.21660
- Liu CY, Chen KF, Chen PJ. Treatment of liver cancer. Cold Spring Harb Perspect Med 2015; 5: a021535. doi: 10.1101/cshperspect.a0215
- Yamashita T, Kaneko S. [Liver Cancer]. [Japanese]. Rinsho Byori 2016; 64: 787–96. PMID: 30695467
- Makovec T. Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapy. Radiol Oncol 2019; 53: 148–58. doi: 10.2478/raon-2019-0018
- Kooiman K, Roovers S, Langeveld SAG, Kleven RT, Dewitte H, O’Reilly MA, et al. Ultrasound-responsive cavitation nuclei for therapy and drug delivery. Ultrasound Med Biol 2020; 46: 1296–325. doi: 10.1016/j.ultrasmedbio.2020.01.002
- Liu S, Zhang Y, Liu Y, Wang W, Gao S, Yuan W, et al. Ultrasound-targeted microbubble destruction remodels tumour microenvironment to improve immunotherapeutic effect. Br J Cancer 2023; 128: 715–25. doi: 10.1038/s41416-022-02076-y
- Chen H, Hwang JH. Ultrasound-targeted microbubble destruction for chemotherapeutic drug delivery to solid tumors. J Ther Ultrasound 2013; 1: 10. doi: 10.1186/2050-5736-1-10
- Schoen S Jr, Kilinc MS, Lee H, Guo Y, Degertekin FL, Woodworth GF, et al. Towards controlled drug delivery in brain tumors with microbubble-enhanced focused ultrasound. Adv Drug Deliv Rev 2022; 180: 114043. doi: 10.1016/j.addr.2021.114043
- Escoffre JM, Sekkat N, Oujagir E, Bodard S, Mousset C, Presset A, et al. Delivery of anti-cancer drugs using microbubble-assisted ultrasound in digestive oncology: from preclinical to clinical studies. Expert Opin Drug Deliv 2022; 19: 421–33. doi: 10.1080/17425247.2022.2061459
- Fu K, Zhou H, Wang C, Gong L, Ma C, Zhang Y, et al. A review: pharmacology and pharmacokinetics of schisandrin A. Phytother Res 2022; 36: 2375–93. doi: 10.1002/ptr.7456
- Wang X, Zhou L, Zhang T, Chen H, Song X, Wang F. Effect and mechanism of schizandrin A in the treatment of liver cancer using network pharmacology, molecular docking, and target validation. Nat Prod Commun 2023; 18: 1–12. doi: 10.1177/1934578X231176916
- Omata D, Munakata L, Kageyama S, Suzuki Y, Maruyama T, Shima T, et al. Ultrasound image-guided gene delivery using three-dimensional diagnostic ultrasound and lipid-based microbubbles. J Drug Target 2022; 30: 200–7. doi: 10.1080/1061186X.2021.1953510
- Zhang J, Yang J, Zhang H, Hu M, Li J, Zhang X. New Span-PEG-composited Fe3O4-CNT as a multifunctional ultrasound contrast agent for inflammation and thrombotic niduses. RSC Adv 2020; 10: 38592–600. doi: 10.1039/d0ra05401a
- Fotakis G, Timbrell JA. In vitro cytotoxicity assays: comparison of LDH, neutral red, MTT and protein assay in hepatoma cell lines following exposure to cadmium chloride. Toxicol Lett 2006; 160: 171–77. doi: 10.1016/j.toxlet.2005.07.001
- Liu Y, Jiang J, Liu C, Zhao W, Ma Y, Zheng Z, et al. Synergistic anti-tumor effect of anti-PD-L1 antibody cationic microbubbles for delivery of the miR-34a gene combined with ultrasound on cervical carcinoma. Am J Transl Res 2021; 13: 988–1005. PMID: 33841635
- Yu B, Sheng D, Tan Q. Determination of schisandrin A and schisandrin B in traditional chinese medicine preparation huganpian tablet by RP-HPLC. Chem Pharm Bull 2019; 67: 713–6. doi: 10.1248/cpb.c18-00968
- Auboire L, Sennoga CA, Hyvelin JM, Ossant F, Escoffre JM, Tranquart F, et al. Microbubbles combined with ultrasound therapy in ischemic stroke: a systematic review of in-vivo preclinical studies. PLoS One 2018; 13: e0191788. doi: 10.1371/journal.pone.0191788
- Lammertink BH, Bos C, Deckers R, Storm G, Moonen CT, Escoffre JM. Sonochemotherapy: from bench to bedside. Front Pharmacol 2015; 6: 138. doi: 10.3389/fphar.2015.00138
- Bouakaz A, Versluis M, Borsboom J, de Jong N. Radial modulation of microbubbles for ultrasound contrast imaging. IEEE Trans Ultrason Ferroelectr Freq Control 2007; 54: 2283–90. doi: 10.1109/tuffc.2007.532
- Rashid M, Zadeh LR, Baradaran B, Molavi O, Ghesmati Z, Sabzichi M, et al. Up-down regulation of HIF-1α in cancer progression. Gene 2021; 798: 145796. doi: 10.1016/j.gene.2021.145796
- Frezzetti D, Gallo M, Maiello MR, D’Alessio A, Esposito C, Chicchinelli N, et al. VEGF as a potential target in lung cancer. Expert Opin Ther Targets 2017; 21: 959–66. doi: 10.1080/14728222.2017.1371137
- Liu XJ, Zhao HC, Hou SJ, Zhang HJ, Cheng L, Yuan S, et al. Recent development of multi-target VEGFR-2 inhibitors for the cancer therapy. Bioorg Chem 2023; 133: 106425. doi: 10.1016/j.bioorg.2023.106425
- Kim KW, Lee SJ, Kim JC. TNF-α upregulates HIF-1α expression in pterygium fibroblasts and enhances their susceptibility to VEGF independent of hypoxia. Exp Eye Res 2017; 164: 74–81. doi: 10.1016/j.exer.2017.08.008
- Wang W, Dong X, Liu Y, Ni B, Sai N, You L, et al. Itraconazole exerts anti-liver cancer potential through the Wnt, PI3K/AKT/mTOR, and ROS pathways. Biomed Pharmacother 2020; 131: 110661. doi: 10.1016/j.biopha.2020.110661
- Liu X, Zhou Q, Hart JR, Xu Y, Yang S, Yang D, et al. Cryo-EM structures of cancer-specific helical and kinase domain mutations of PI3Kα. Proc Natl Acad Sci U S A 2022; 119: e2215621119. doi: 10.1073/pnas.2215621119
- Xiang X, Zhao J, Xu G, Li Y, Zhang W. mTOR and the differentiation of mesenchymal stem cells. Acta Biochim Biophys Sin 2011; 43: 501–10. doi: 10.1093/abbs/gmr041
- Tian LY, Smit DJ, Jücker M. The Role of PI3K/AKT/mTOR Signaling in hepato-cellular carcinoma metabolism. Int J Mol Sci 2023; 24: 2652. doi: 10.3390/ijms24032652